Chengdu Kendite Biomedical Technology Co. Ltd. has synthesized pyrimidopyrazole compounds acting as non-receptor tyrosine-protein kinase TYK2 (JH2 domain) inhibitors. They are reported to be useful for the treatment of cancer, neurodegeneration, autoimmune disease, dermatological and inflammatory disorders.
Prospect Therapeutics Inc. has synthesized new substituted tricyclic derivatives acting as tyrosine-protein kinase JAK1 and non-receptor tyrosine-protein kinase TYK2 inhibitors.
Sundance Biosciences Inc. has discovered non-receptor tyrosine-protein kinase TYK2 inhibitors potentially useful for the treatment of multiple sclerosis.
TYK2, a Janus kinase family member, mediates signaling from pro-inflammatory cytokines such as type I interferons, IL-12 and IL-23. In multiple sclerosis (MS), chronic CNS inflammation involves glial activation and immune cell infiltration, making TYK2 inhibition a potential strategy to reduce neuroinflammation.
Sundance Biosciences Inc. has discovered non-receptor tyrosine-protein kinase TYK2 inhibitors potentially useful for the treatment of multiple sclerosis.
The compound, which showed oral bioavailability of 42.7%, performed similarly well as the licensed drug loratidine in a mouse model of the inflammatory disease allergic rhinitis.
Formation Bio Inc. acquired ex-China rights to Lynk Pharmaceuticals Co. Ltd.’s oral TYK2-inhibitor, LNK-01006, for up to $605 million. The phase I-ready central nervous system (CNS) candidate will be developed at Formation’s newly formed subsidiary, Bleecker Bio.
Formation Bio Inc. acquired ex-China rights to Lynk Pharmaceuticals Co. Ltd.’s oral TYK2-inhibitor, LNK-01006, for up to $605 million. The phase I-ready central nervous system (CNS) candidate will be developed at Formation’s newly formed subsidiary, Bleecker Bio.
Lynk Pharmaceuticals Co. Ltd. has received IND clearance from the FDA for LNK-01006, an allosteric TYK2 inhibitor with potential to treat neurodegenerative diseases.
